Related Experiment Video
Updated: Jul 2, 2026
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Published on: May 14, 2019
A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL
Chenguang Wang1, Xiangrong Geng1, Suhaib Abdelrahman1
1University of Michigan, Ann Arbor, Michigan, United States.
Abstract:
Primary cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of extranodal non-Hodgkin lymphomas. Outcomes for patients with advanced-stage disease are suboptimal, as few complete and durable responses are achieved with currently available therapeutic agents. However, improved understanding of oncogenic transcriptional programs in malignant T cells and their engagement with the tumor microenvironment (TME) may unveil therapeutic vulnerabilities. Therefore, we have compiled the largest available scRNA-seq CTCL atlas that includes >2 million skin and blood cells from 116 individual patients. We identified recurrent transcriptional programs in malignant T cells, a subset of which are associated with GATA-3 dependent transcriptional programs, especially in the setting of large cell transformation and advanced-stage disease. Many of the transcriptional programs identified are therapeutically targetable with clinically available agents, including HDAC, XPO1, CDK9, JAK/CSF1R, and IKZF1/IKZF3 antagonists. The CTCL TME is dominated by infiltrating and exhausted effector and cytotoxic T cells that are restrained by a robust infiltrate of regulatory T cells, transcriptionally polarized monocytes/macrophages, and cancer-associated fibroblasts. Collectively, these findings have significant implications for the rationale design of combinatorial strategies targeting immune checkpoints, including PD-1. We have identified transcriptional programs, driven by oncogenic transcription factors, and constituents of the TME as therapeutic vulnerabilities in CTCL, and hope that the CTCL atlas constructed will provide a valuable resource for future studies exploiting these therapeutic vulnerabilities.
Insights
This study reveals new therapeutic targets in cutaneous T-cell lymphoma (CTCL) by analyzing a large dataset of patient cells. Identifying specific gene activity in cancer cells and their environment offers hope for better treatments.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Primary cutaneous T-cell lymphomas (CTCL) are aggressive cancers with poor outcomes in advanced stages.
- Current therapies offer limited durable responses, highlighting the need for novel treatment strategies.
Purpose of the Study:
- To create the largest single-cell RNA sequencing (scRNA-seq) atlas of CTCL, encompassing over 2 million cells from 116 patients.
- To identify oncogenic transcriptional programs in malignant T cells and their interaction with the tumor microenvironment (TME).
- To uncover potential therapeutic vulnerabilities and guide the development of new combinatorial treatments.
Main Methods:
- Compiled and analyzed a comprehensive scRNA-seq dataset from CTCL patient skin and blood samples.
- Identified recurrent transcriptional programs in malignant T cells, including GATA-3 dependent pathways.
- Characterized the cellular composition and immune landscape of the CTCL TME.
Main Results:
- Discovered specific transcriptional programs in malignant T cells, particularly in advanced-stage disease and large cell transformation.
- Found that many identified transcriptional programs are targetable with existing drugs (e.g., HDAC, XPO1, CDK9 inhibitors).
- Characterized the CTCL TME as a complex ecosystem involving exhausted T cells, regulatory T cells, specific myeloid cells, and fibroblasts.
Conclusions:
- The CTCL atlas provides a valuable resource for understanding disease biology and identifying therapeutic targets.
- Targeting identified oncogenic transcriptional programs and TME components offers promising avenues for novel combinatorial therapies, including immune checkpoint inhibitors.
- Findings support the rational design of combination strategies to improve outcomes for advanced-stage CTCL patients.
Related Concept Videos
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...